Interest in Novel Lymphoma Drug Expands to Two Key Subtypes

By News Health
2 months Ago

(MedPage Today) — HOUSTON — Already indicated for relapsed/refractory follicular lymphoma, the bispecific antibody mosunetuzumab (Lunsumio) showed early promise for improving outcomes in two key lymphoma subtypes, according to studies reported…

Source link : https://www.medpagetoday.com/meetingcoverage/soho/117371

Author :

Publish date : 2025-09-09 14:53:00

Copyright for syndicated content belongs to the linked Source.

Categories: Health News

Related Content

Healthy Diet May Cut Heart Risk in Patients With CVD

Older Antihistamines Tied to Delirium in Older Patients

Use of IV Magnesium Sulphate Tied to Lower Mortality in ARDS

'We begged for years but the help wasn't there'

Novel PRP Approach Improves GSM in Cancer Survivors

Peer Mentors Guide Youth From Pediatric to Adult Heart Care